Decreased antipyrine clearance following endotoxin administration: In vivo evidence of the role of nitric oxide

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2697-2701

  Kitaichi, Kiyoyuki ^a   Wang, Li ^a,b   Takagi, Kenji ^a   Iwase, Mitsunori ^a   Shibata, Eiji ^a   Nadai, Masayuki ^c   Takagi, Kenzo ^a   Hasegawa, Takaaki ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b WEST CHINA UNIVERSITY OF MEDICAL SCIENCES   (China)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; ENDOTOXIN; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; PHENAZONE; THIOUREA DERIVATIVE;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032729630     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2697     Document Type: Article

References (34)

1. Bredt, D. S., and S. H. Snyder. 1994. Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 43:175-195.
2. Donate, M. T., M. I. Guillen, R. Jover, J. V. Castell, and M. J. Gomez-Lechon. 1997. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-γ in human hepatocytes. J. Pharmacol. Exp. Ther. 281:484-490.
3. Engel, G., U. Hofmann, H. Heidemann, J. Cosme, and M. Eichelbaum. 1996. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59: 613-623.
4. Fukujama, S., T. Azuma, Y. Hirasawa, N. Morokoshi, T. Akama, S. Koda, and Y. Kita. 1996. Nitric oxide (NO)-releasing pathway of FK409 in the presence of sulfhydryl-bearing compounds. Pharm. Res. 13:1238-1242.
5. Gergel, D., V. Misik, P. Riesz, and A. I. Cederbaum. 1997. Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide. Arch. Biochem. Biophys. 337:239-250.
6. Ghezzi, P., B. Saccardo, P. Villa, V. Rossi, M. Blanchi, and C. A. Dinarello. 1986. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect. Immun. 54:837-840.
7. Hasegawa, T., M. Ohta, M. Mori, I. Nakashima, and N. Kato. 1983. The Klebsiella O3 lipopolysaccharide isolated from culture fluid: structure of the polysaccharide moiety. Microbiol. Immunol. 27:683-694.
8. -). Chem. Pharm. Bull. (Tokyo) 33:333-339.
9. Hodgson, P. D., and K. W. Renton. 1995. The role of nitric oxide generation in interferon-evoked cytochrome P450 down-regulation. Int. J. Immunopharmacol. 17:995-1000.
10. Inaba, T., S. V. Otton, and W. Kalow. 1980. Deficient metabolism of debrisoquine and sparteine. Clin. Pharmacol. Ther. 27:547-549.
11. Khatsenko, O., and Y. Kikkawa. 1997. Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. J. Pharmacol. Exp. Ther. 280:1463-1470.
12. Khatsenko, O. G., S. S. Gross, A. B. Rifkind, and J. R. Vane. 1993. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc. Natl. Acad. Scii. USA 90:11147-11151.
13. Kita, Y., S. Fukuyama, and Y. Hirasawa. 1995. Close correlation between nitric oxide (NO) formation from NO releasers and the biological activities of these agents in rats. Jpn. J. Pharmacol. 65:69-74.
14. Kita, Y., Y. Hirasawa, S. Fukuyama, K. Ohkubo, Y. Kato, H. Takamatsu, M. Ohno, S. Nishino, M. Kato, and J. Seki. 1996. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners. J. Pharmacol. Exp. Ther. 276: 421-425.
15. Kurokohchi, K., H. Yoneyama, Y. Matsuo, M. Nishloka, and Y. Ichikawa. 1992. Effects of interleukin 1α on the activities and gene expressions of the cytochrome P450IID subfamily. Biochem. Pharmacol. 44:1669-1674.
16. Minamiyama, Y., S. Takemura, S. Imaoka, Y. Funae, Y. Tanimoto, and M. Inoue. 1997. Irreversible inhibition of cytochrome P450 by nitric oxide. J. Pharmacol. Exp. Ther. 283:1479-1485.
17. Moncada, S., R. M. Palmer, and E. A. Higgs. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:109-142.
18. Morgan, E. T. 1997. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 29:1129-1188.
19. Morgan, E. T., K. B. Thomas, R. Swanson, T. Vales, J. Hwang, and K. Wright. 1994. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim. Biophys. Acta 1219:475-483.
20. Morris, S. M., Jr., and T. R. Billiar. 1994. New insights into the regulation of inducible nitric oxide synthesis. Am. J. Physiol. 266:E829-E839.
21. Nadai, M., T. Sekido, I. Matsuda. L. Wang, K. Kitalchi, A. Itoh, T. Nabeshima, and T. Hasegawa. 1998. Time-dependent effects of Klebsiella pneumoniae endotoxin on drug-metabolizing enzyme activity in rats. J. Pharm. Pharmacol. 50:871-879.
22. Nadin, L., A. M. Butler, G. C. Farrell, and M. Murray. 1995. Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor alpha. Gastroenterology 109:198-205.
23. Ohta, M., M. Mori, T. Hasegawa, F. Nagase, I. Nakashima, S. Naito, and N. Kato. 1981. Further studies of the polysaccharide of Klebsiella pneumoniae possessing strong adjuvanticity. I. Production of the adjuvant polysaccharide by noncapsulated mutant. Microbiol. Immunol 25:939-948.
24. Pilsgaard, H., and H. E. Poulsen. 1984. A one-sample method for antipyrine clearance determination in rats. Pharmacology 29:110-116.
25. Sewer, M. B., T. B. Barclay, and E. T. Morgan. 1998. Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol. Pharmacol. 54:273-279.
26. Sewer, M. B., and E. T. Morgan. 1997. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1β and endotoxin in primary rat hepatocytes. Biochem. Pharmacol. 54:729-737.
27. Shedlofsky, S. I., B. C. Israel, C. J. McClain, D. B. Hill, and R. A. Blouin. 1994. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Investig. 94:2209-2214.
28. Sonne, J., M. Dossing, S. Loft, and P. B. Andreasen. 1985. Antipyrine clearance in pneumonia. Clin. Pharmacol. Ther. 37:701-704.
29. Stadler, J., J. Trockfeld, W. A. Schmalix, T. Brill, J. R. Siewert, H. Greim, and J. Doehmer. 1994. Inhibition of cytochromes P4501A by nitric oxide. Proc. Natl. Acad. Sci. USA 91:3559-3563.
30. Szabo, C., G. J. Southan, and C. Thiemermann. 1994. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA 91:12472-12476.
31. Vos, T. A., A. S. Gouw, P. A. Klok, R. Havinga, H. van Goor, S. Huitema, H. Roelofsen, F. Kuipers, P. L. Jansen, and H. Moshage. 1997. Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 113:1323-1333.
32. Wink, D. A., Y. Osawa, J. F. Derbyshire, C. R. Jones, S. C. Eshenaur, and R. W. Nims. 1993. Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch. Biochem. Biophys. 300:115-123.
33. Wright, K., and E. T. Morgan. 1991. Regulation of cytochrome P450IIC12 expression by interleukin-1α, interleukin-6, and dexamethasone. Mol. Pharmacol. 39:468-474.
34. Yamaoka, K., Y. Tanigawara, T. Nakagawa, and T. Uno. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 4:879-885.